R‐flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's Disease as determined by MEMRI

Axonal pathology is a prevalent feature of Alzheimer's disease (AD) and is thought to occur predominantly due to the accumulation of amyloid beta (Aβ). However, it remains unclear whether therapeutics geared toward reducing Aβ improves axonal deficits. We have previously used Manganese Enhanced MRI to demonstrate that axonal transport deficits occur before plaque formation in the Tg2576 mouse model of Alzheimer's disease. Here we tested whether axonal transport deficits in the Tg2576 mouse model improve in response to the Aβ42 selective lowering agent R‐Flurbiprofen (R‐F). We demonstrated that in young animals (before Aβ plaque formation), R‐F treatment reduced Aβ42 levels and coincided with a significant improvement in axonal transport (P = 0.0186). However, in older animals (after plaque formation had occurred), we observed that R‐F treatment did not reduce Aβ42 levels although we still observed a significant improvement in axonal transport as assessed with MEMRI (P = 0.0329). We then determined that R‐F treatment reduced tau hyper‐phosphorylation in the older animals. These data indicate that both Aβ42 and tau comprise a role in axonal transport rate deficits in the Tg2576 model of Alzheimer's Disease. Magn Reson Med, 2011. © 2010 Wiley‐Liss, Inc.

[1]  S. Weggen,et al.  Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. , 2003, The Journal of biological chemistry.

[2]  A. Sbarbati,et al.  Magnetic resonance imaging of the rat Harderian gland , 2002, Journal of anatomy.

[3]  Gerd Geisslinger,et al.  Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Jeffrey A. Johnson,et al.  Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways , 2002, The Journal of Neuroscience.

[5]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[6]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[7]  Takashi Morihara,et al.  Selective inhibition of Aβ42 production by NSAID R‐enantiomers , 2002 .

[8]  E. Mandelkow,et al.  Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses , 2003, Neurobiology of Aging.

[9]  Hui Zheng,et al.  In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease , 2007, NeuroImage.

[10]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[11]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[12]  J. Mariani,et al.  β-Amyloid(1–42) induces a reduction in the parallel fiber responses of Purkinje cells: Possible involvement of pro-inflammatory processes , 2007, Experimental Gerontology.

[13]  T. Gómez-Isla,et al.  Expression of stress‐activated kinases c‐Jun N‐terminal kinase (SAPK/JNK‐P) and p38 kinase (p38‐P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice , 2004, Neuropathology and applied neurobiology.

[14]  T. Golde,et al.  Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice , 2007, BMC Neuroscience.

[15]  C. Greer,et al.  Cytoskeletal organization of the developing mouse olfactory nerve layer , 2006, The Journal of comparative neurology.

[16]  G. Johnson,et al.  Tau phosphorylation in neuronal cell function and dysfunction , 2004, Journal of Cell Science.

[17]  S. Grösch,et al.  Activation of c‐Jun‐N‐terminal‐kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  K. Jellinger,et al.  Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease , 1989, Brain Research.

[19]  C. Xie.  Calcium-regulated signaling pathways , 2007, NeuroMolecular Medicine.

[20]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[21]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[22]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[23]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[24]  Khadija Iqbal,et al.  Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease , 1991, Brain Research.

[25]  F. Leuven,et al.  Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease , 2002, NeuroMolecular Medicine.

[26]  T. Kawakami,et al.  Glutamate and Amyloid β-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms , 2003, The Journal of Neuroscience.

[27]  Z. Muresan,et al.  Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? , 2009, Future neurology.

[28]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[29]  G. Cole,et al.  Selective inhibition of Abeta42 production by NSAID R-enantiomers. , 2002, Journal of neurochemistry.

[30]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[31]  H. Schaible,et al.  Inhibition of Noxious Stimulus‐Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers , 2000, Journal of neurochemistry.